Clinicians offer insights into promising drugs in the pipeline

  • May 22, 2013
  • Read the Perspective from Patrick C. Ma, MD, MS

The May 25 issue of HemOnc Today includes the annual Oncology Drugs in the Pipeline chart, which lists drugs in phase 2 or phase 3 development for a variety of indications.

To coincide with the publication of the chart, HemOnc Today asked several clinicians to offer their perspectives about the drugs in the pipeline they believe are most promising for their specialties.

Full Story »
  • Filter By:
  • FDA advisory panel decisions
  • FDA grants priority review for T-DM1

  • HemOnc Today, December 10, 2012
  • The FDA has granted priority review designation for the breast cancer drug trastuzumab emtansine.
    Trastuzumab emtansine (T-DM1; Immunogen, Genentech) is...More »
  • Breast Tomosynthesis

  • November 3, 2012
  • The DBT system employs a digital X-ray that records a series of low-dose, high-resolution images of the breast while traversing a small (15°) arc around ......More »

Personalize your page!

Register for Healio to get content tailored to your specialty and areas of interest. It’s FREE and only takes one minute. Register now!

More»
  • HemOncToday Blog
  • William Wood, MD
  • Contending with ‘Dr.’ Google
  • How active are your patients in consulting “Dr. Google” — and how do you think this process might become more effective, and more safe?
More»
  • Healio Minute, May 24, 2013
  • Healio Minute logo
  • CVD drug, EHRs, PICUs
  • Cancer drug shows new side, EHRs tip the balance and PICUs found risky in winter.
More »
[X]